Skip to main content
PharmaResources (Shanghai) Co., Ltd. logo

PharmaResources (Shanghai) Co., Ltd. — Investor Relations & Filings

Ticker · 301230 ISIN · CNE1000065Q9 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 458 across all filing types
Latest filing 2024-11-18 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 301230

About PharmaResources (Shanghai) Co., Ltd.

https://www.pharmaresources.cn

PharmaResources (Shanghai) Co., Ltd. is a comprehensive Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) specializing in small molecule drug discovery and development. The company provides an integrated platform of services including medicinal chemistry, custom synthesis, process research and development, and analytical chemistry. PharmaResources supports global pharmaceutical and biotechnology partners through the entire drug development lifecycle, from initial lead optimization to the commercial-scale manufacturing of advanced intermediates and Active Pharmaceutical Ingredients (APIs). With a focus on technical innovation and quality management, the firm utilizes advanced synthetic methodologies and process engineering to accelerate drug candidates toward clinical trials and market approval.

Recent filings

Filing Released Lang Actions
北京市嘉源律师事务所关于上海泓博智源医药股份有限公司2024年第三次临时股东大会的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening, procedures, attendance, and voting results of the 2024 third extraordinary general meeting of shareholders of Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. It details the legal compliance of the meeting process and validates the voting outcomes. It does not contain financial statements or financial performance data, nor is it a report of the meeting itself or a notice of voting results. Instead, it is a legal opinion on the meeting's legality and procedures. This type of document is best classified under Regulatory Filings (RNS) as it is a compliance/legal document related to corporate governance and shareholder meetings but does not fit into other specific categories such as Declaration of Voting Results (DVA) or Proxy Solicitation (PSI). The document length is under 5,000 characters and is a standalone legal opinion letter, not a report or announcement of a report publication.
2024-11-18 Chinese
关于 2024 年限制性股票激励计划内幕信息知情人买卖公司股票的自查报告
Regulatory Filings Classification · 95% confidence The document is a self-inspection report regarding insider trading related to a 2024 restricted stock incentive plan. It details the investigation of stock transactions by insiders during a specified period, confirming no misuse of insider information. The document references regulatory compliance and disclosures but does not contain financial statements or earnings data. It is a regulatory announcement about insider trading checks related to a stock incentive plan, not a financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS). The document length is short (2017 characters), and it is a formal announcement rather than a report or presentation.
2024-11-18 Chinese
监事会关于公司2024年限制性股票激励计划首次授予激励对象名单的核查意见及公示情况说明
Board/Management Information Classification · 95% confidence The document is an official announcement from the supervisory board of Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. regarding the verification and public disclosure of the list of recipients for the company's 2024 restricted stock incentive plan's first grant. It details the public notice period, verification methods, and compliance with relevant laws and regulations. The document does not contain financial statements or detailed financial data but focuses on the stock incentive plan and related governance matters. It is not a full annual or interim report, nor an earnings release or audit report. It is also not a proxy solicitation or voting result announcement. The content aligns with disclosures related to management or board-related information about stock incentive plans and their recipients. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length is short (2182 characters), and it is a direct announcement, not a report publication announcement or regulatory filing fallback.
2024-11-12 Chinese
关于股东减持公司股份达到 1%暨减持计划实施完成的公告
Major Shareholding Notification Classification · 100% confidence The document is an official announcement regarding a shareholder's reduction of company shares reaching 1%, detailing the completion of the share reduction plan. It includes specifics about the shareholder, reduction methods, dates, prices, and shareholding changes. The document references compliance with securities laws and stock exchange regulations. It does not contain financial statements or detailed financial performance data, nor is it a report or presentation. The content fits the definition of a Major Shareholding Notification, which involves notifying changes in significant share ownership levels crossing thresholds. The document length is under 5,000 characters and is a formal announcement, not a report or certification. Therefore, the appropriate classification is Major Shareholding Notification (MRQ).
2024-11-11 Chinese
关于回购公司股份的进展公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement from Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. regarding the progress of its share repurchase program. It details the number of shares repurchased, prices, total amount spent, and compliance with regulatory requirements. The text references previous announcements about the share repurchase plan and adjustments to the repurchase price limits. The document is not a full financial report but a progress update on the company's share buyback activity. This fits the category of 'Transaction in Own Shares' (POS), which covers reports of the company buying back its own shares. The document length is 2259 characters, which is consistent with a detailed announcement rather than a full report or a brief notice. Therefore, the correct classification is POS with high confidence.
2024-11-04 Chinese
上海泓博智源医药股份有限公司2024年限制性股票激励计划实施考核管理办法
Governance Information Classification · 95% confidence The document is titled as the "2024 Restricted Stock Incentive Plan Implementation Assessment Management Measures" for Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. It details the company's internal procedures for assessing performance related to a restricted stock incentive plan, including assessment principles, committees involved, performance targets, and management of results. It is a governance-related document focused on incentive plan implementation and performance evaluation, not a financial report, earnings release, or regulatory filing. It is not an announcement of voting results or a proxy statement, but rather a detailed internal governance policy. Therefore, the document best fits the category of Governance Information (CGR). The document length is 3401 characters, which is relatively short but contains substantive governance content rather than just an announcement or notice.
2024-10-31 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.